ZA868039B - Sustained release tablets - Google Patents

Sustained release tablets

Info

Publication number
ZA868039B
ZA868039B ZA868039A ZA868039A ZA868039B ZA 868039 B ZA868039 B ZA 868039B ZA 868039 A ZA868039 A ZA 868039A ZA 868039 A ZA868039 A ZA 868039A ZA 868039 B ZA868039 B ZA 868039B
Authority
ZA
South Africa
Prior art keywords
sustained release
release tablets
tablets
sustained
release
Prior art date
Application number
ZA868039A
Other languages
English (en)
Inventor
Peter Lloyd Oren
Werner Max Karl Seidler
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA868039B publication Critical patent/ZA868039B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA868039A 1985-10-25 1986-10-22 Sustained release tablets ZA868039B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/791,282 US4753801A (en) 1985-10-25 1985-10-25 Sustained release tablets

Publications (1)

Publication Number Publication Date
ZA868039B true ZA868039B (en) 1988-05-25

Family

ID=25153218

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA868039A ZA868039B (en) 1985-10-25 1986-10-22 Sustained release tablets

Country Status (5)

Country Link
US (1) US4753801A (de)
EP (1) EP0221732A3 (de)
JP (1) JPS62106011A (de)
AU (1) AU590343B2 (de)
ZA (1) ZA868039B (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE63321B1 (en) * 1986-02-03 1995-04-05 Elan Corp Plc Drug delivery system
DE3776116D1 (de) * 1986-12-30 1992-02-27 American Cyanamid Co Zusammensetzung die ein polycarbophil enthaelt.
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
ES2061623T3 (es) * 1987-03-02 1994-12-16 Brocades Pharma Bv Procedimiento para la obtencion de una composicion farmaceutica y un granulado farmaceutico.
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
US4806359A (en) * 1987-04-22 1989-02-21 Mcneilab, Inc. Iburprofen sustained release matrix and process
US5004613A (en) * 1987-07-27 1991-04-02 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
JP2708803B2 (ja) * 1987-09-02 1998-02-04 中外製薬株式会社 持続放出製剤
US5211958A (en) * 1987-11-30 1993-05-18 Gist-Brocades, N.V. Pharmaceutical composition and process for its preparation
ATE108996T1 (de) * 1988-02-25 1994-08-15 Brocades Pharma Bv Verfahren zur herstellung eines pharmazeutischen granulats.
FR2640138B1 (fr) * 1988-12-13 1993-08-20 Medibrevex Procede d'obtention de formes galeniques a base de composes pharmaceutiques actifs pour administration par voie per- et sublinguale
US5104648A (en) * 1989-02-02 1992-04-14 Mallinckrodt Specialty Chemicals Company High ibuprofen content granulations
US4911921A (en) * 1989-02-02 1990-03-27 Mallinckrodt, Inc. High ibuprofen content granulations
US4956171A (en) * 1989-07-21 1990-09-11 Paco Pharmaceutical Services, Inc. Transdermal drug delivery using a dual permeation enhancer and method of performing the same
US5358717A (en) * 1989-12-22 1994-10-25 Syntex (U.S.A.) Inc. Directly-compressible naproxen or naproxen sodium compositions
PT96229B (pt) * 1989-12-22 1998-06-30 Syntex Pharma Int Processo para a preparacao de composicoes farmaceuticas em po, secas por pulverizacao, directamente compressiveis em comprimidos, contendo naproxeno ou naproxeno sodico
SK117793A3 (en) * 1991-04-29 1994-05-11 Merck & Co Inc Optimized tablet formulation
JPH0667153U (ja) * 1993-03-03 1994-09-20 麻衣子 斎藤 踏み違えない自動車のペダル
IL109097A0 (en) * 1993-04-03 1994-06-24 Knoll Ag Delayed release micro tablet of beta-phenylpropiophenone derivatives and its production
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
BE1009856A5 (fr) * 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US5989591A (en) * 1997-03-14 1999-11-23 American Home Products Corporation Rapamycin formulations for oral administration
CN1277550A (zh) * 1997-09-11 2000-12-20 尼科梅德丹麦有限公司 非甾体抗炎药物(NSAIDs)的改进释放的复合型组合物
NZ333474A (en) * 1998-01-02 1999-06-29 Mcneil Ppc Inc A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
US6197347B1 (en) 1998-06-29 2001-03-06 Andrx Pharmaceuticals, Inc. Oral dosage for the controlled release of analgesic
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
DE19961897A1 (de) * 1999-12-20 2001-06-28 Basf Ag Verwendung eines Filmüberzuges als geschmacksmaskierendes Coating von pharmazeutischen Darreichungsformen
EP1272181A2 (de) * 2000-04-13 2003-01-08 Synthon B.V. Arzneizubereitungen mit gesteuerter wirkstoffabgabe enthaltend ein hypnotikum
WO2002060446A1 (en) * 2001-01-29 2002-08-08 Shionogi & Co., Ltd. Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US20070184104A1 (en) * 2001-10-25 2007-08-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
KR100767271B1 (ko) * 2003-07-11 2007-10-17 에프. 호프만-라 로슈 아게 사퀴나비르 메실레이트 경구 투여 형태
TW200507882A (en) * 2003-07-17 2005-03-01 Kyowa Hakko Kogyo Kk Solid formulations
US20050163847A1 (en) * 2004-01-21 2005-07-28 Andrx Pharmaceuticals, Llc Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug
US7709025B2 (en) * 2004-03-31 2010-05-04 Bpsi Holdings, Inc. Enteric coatings for orally ingestible substrates
US20060258708A1 (en) * 2005-05-16 2006-11-16 Andrulis Peter J Jr Method for treating Parkinson's disease and other neurological diseases
US20070036859A1 (en) * 2005-08-11 2007-02-15 Perry Ronald L Sustained release antihistamine and decongestant composition
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
BRPI0917444A2 (pt) 2008-08-15 2015-12-01 Depomed Inc composições farmacêuticas de retenção gástrica para o tratamento e prevenção de doenas do snc
PL2872121T3 (pl) 2012-07-12 2019-02-28 SpecGx LLC Kompozycje farmaceutyczne o przedłużonym uwalnianiu, zniechęcające do nadużywania
JP6441890B2 (ja) 2013-03-15 2018-12-19 ブレインツリー・ラボラトリーズ，インコーポレイテッド 硫酸塩の両用経口薬学的組成物錠剤およびその使用の方法
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264573A (en) * 1979-05-21 1981-04-28 Rowell Laboratories, Inc. Pharmaceutical formulation for slow release via controlled surface erosion
US4465660A (en) * 1981-04-01 1984-08-14 Mead Johnson & Company Sustained release tablet containing at least 95 percent theophylline
US4447443A (en) * 1982-11-15 1984-05-08 Merck & Co., Inc. Anti-inflammatory/analgesic combination of α-fluoromethylhistidine and a selected non-steroidal anti-inflammatory drug (NSAID)
AU570937B2 (en) * 1982-12-09 1988-03-31 Stephen A. Cooper Synergistic composition of hydroxyzine and salts thereof with nsaids
US4539198A (en) * 1983-07-07 1985-09-03 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range
JPH0647532B2 (ja) * 1983-08-31 1994-06-22 ジ アツプジヨン カンパニ− 歯槽骨吸収の治療

Also Published As

Publication number Publication date
AU590343B2 (en) 1989-11-02
EP0221732A3 (de) 1987-10-28
US4753801A (en) 1988-06-28
JPS62106011A (ja) 1987-05-16
AU6431686A (en) 1987-04-30
US4753801B1 (de) 1992-07-14
EP0221732A2 (de) 1987-05-13

Similar Documents

Publication Publication Date Title
ZA868039B (en) Sustained release tablets
NZ217387A (en) Controlled release tablets
GB8500639D0 (en) Fast-starting sustained release tablet
EP0187703A3 (en) Sustained release preparation
ZA874315B (en) Sustained release capsule
PH24205A (en) Sustained release dosage forms
GB8603231D0 (en) Release mechanism
EP0297625A3 (en) Pressure-sensitive tablet
ZA851891B (en) Sustained release pharmaceutical capsules
GB8510639D0 (en) Drug release device
GB8525348D0 (en) Effervescent tablets
AU95930S (en) Tablet
GB2176999B (en) Sustained release medicament
GB8518927D0 (en) Tablets
GB2188915B (en) Tablets
AU100293S (en) Tablet
GB8430703D0 (en) Drug release devices
ZA853109B (en) Drug release device
GB8623087D0 (en) Release unit
IE851357L (en) Sustained release composition
CA56775S (en) Tablet
CA56776S (en) Tablet
IE872675L (en) Sustained release pharmaceutical
CS969985A1 (en) Zpusob pripravy tablet z aktivniho uhli
GB8505410D0 (en) Release devices